JavaScript is disabled. Please enable to continue!
Services >> Efficacy >> Gastrointestinal

In vivo GI models tailored to advance your program

Sidebar Image

Gastrointestinal (GI) disease is characterized by abnormalities in the gastrointestinal tract which includes the esophagus, liver, gallbladder, stomach, pancreas, intestines and colon.  Inflammation in these areas can cause a variety of GI diseases or dysfunctions and can be difficult to diagnose. According to the CDC, in the United States alone, inflammatory bowel disease (Crohn's disease or ulcerative colitis) affects over 1 million people.

Eurofins Pharma Discovery Services has conducted in vivo testing for both side-effect profiling and efficacy in GI disease for over 30 years.  Our models allow examination of GI motility and colonic function or to test agents designed to prevent a variety of GI related diseases.  They also employ a broad range of outcome measures to assess GI safety and/or therapeutic efficacy of novel test articles. 

Advantages of Gastrointestinal studies with Eurofins:

  • Major therapeutically relevant models, including:
    • Gastric acid secretion and ulcers
    • Mucosal irritation
    • Inflammatory bowel disease (IBD)
    • Irritable bowel syndrome (IBS)
    • Emesis, including 5-HT emetic models
  • Companion services can monitor blood or organ exposure and biomarker analysis for PK/PD assessment